Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching Placebo
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
Conditions
Chronic Spontaneous Urticaria
Interventions
EVO756, Placebo control
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
132
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 104 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open-label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 27 more
Conditions
Chronic Spontaneous Urticaria, CSU
Interventions
Ritlecitinib
Drug
Lead sponsor
Ahuva D Cices
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Kirksville, Missouri
Not listed Phase 4 Interventional Accepts healthy volunteers

Molecular Endotypes of Chronic Idiopathic Urticaria

NCT04774315
Conditions
Chronic Urticaria, Idiopathic
Interventions
Omalizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
North Miami Beach, Florida • Glenview, Illinois
Conditions
Chronic Spontaneous Urticaria
Interventions
AK006 IV
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
Conditions
Urticaria
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
Conditions
Chronic Spontaneous Urticaria
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Bakersfield, California • Fountain Valley, California • Lancaster, California + 13 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Conditions
Urticaria
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Conditions
Urticaria Chronic
Interventions
Placebo, 0.5 mg epinephrine, 1 mg epinephrine
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glenview, Illinois • Cincinnati, Ohio